对熊去氧胆酸应答不佳的原发性胆汁性胆管炎治疗策略

施漪雯; 尤红

doi:10.3969/j.issn.1001-5256.2017.11.010

对熊去氧胆酸应答不佳的原发性胆汁性胆管炎治疗策略

DOI: 10.3969/j.issn.1001-5256.2017.11.010

施漪雯,
尤红

首都医科大学附属北京友谊医院肝病研究中心肝硬化转化医学北京市重点实验室国家消化系统疾病临床医学研究中心

详细信息

中图分类号: R575.22
计量
- 文章访问数: 2641
- HTML全文浏览量: 8
- PDF下载量: 537
- 被引次数: 0
出版历程
- 收稿日期: 2017-09-03
- 出版日期: 2017-11-20

Therapeutic strategies for patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid

Shi YiWen,
You Hong

Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing Key Laboratory of Translational Medicine in Liver Cirrhosis, National Clinical Research Center for Digestive Diseases

摘要

摘要: 原发性胆汁性胆管炎(PBC)的治疗近年来主要应用熊去氧胆酸,而增长的患者人数、应答不佳和治疗不耐受的出现对治疗方案提出了挑战,新药奥贝胆酸的获批为PBC患者带来了希望,联合使用贝特类药物也具有前景,更多的试验正在进行之中。新型药物如单克隆抗体、成纤维细胞生长因子19、钠依赖性胆汁酸转运蛋白抑制剂等虽然疗效数据有限,但为PBC治疗提供了新的方向。通过个性化随访以及分层治疗,PBC患者的管理将进入新的阶段。
- 胆管炎,胆汁性 /
- 熊脱氧胆酸 /
- 鹅脱氧胆酸 /
- 氯贝酸 /
- 糖皮质激素类 /
- 抗体,单克隆
Abstract: In recent years, ursodeoxycholic acid is commonly used for the treatment of primary biliary cholangitis (PBC) ;however, the growing number of PBC patients and the occurrence of suboptimal response and treatment intolerance pose a great challenge to treatment regimens.The approval of the new drug obeticholic acid brings hope to PBC patients, and a combination of fibrates also has a promising future.More studies are in progress.Although new drugs, such as monoclonal antibody, fibroblast growth factor 19, and sodium-dependent bile acid transporter inhibitor, have limited efficacy data, they provide new directions for the treatment of PBC.With the help of individualized follow-up and stratified therapy, the management of PBC patients will enter a new stage.
- cholangitis, biliary /
- ursodeoxycholic acid /
- chenodeoxycholic acid /
- clofibric acid /
- glucocrticoids /
- antibodies, monoclonal

HTML全文

参考文献(21)

[1]BOSCH A, DUMORTIER J, MAUCORT-BOULCH D, et al.Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence[J].J Hepatol, 2015, 63 (6) :1449-1458.

[2]Chinese Society of Hepatology, Chinese Medical Association;Chinese Society of Gastroenterology, Chinese Medical Association;Chinese Society of Infectious Diseases, Chinese Medical Association.Consensuson the diagnosis and management of primary biliary cirrhosis (cholangitis) (2015) [J].J Clin Hepatol, 2015, 31 (12) :1980-1988. (in Chinese) 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会.原发性胆汁性肝硬化 (又名原发性胆汁性胆管炎) 诊断和治疗共识 (2015) [J].临床肝胆病杂志, 2015, 31 (12) :1980-1988.

[3]NEUSCHWANDER-TETRI BA.Targeting the FXR nuclear receptor to treat liver disease[J].Gastroenterology, 2015, 148 (4) :704-706.

[4]HIRSCHFIELD GM, MASON A, LUKETIC V, et al.Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid[J].Gastroenterology, 2015, 148 (4) :751-761.e758.

[5]NEVENS F, ANDREONE P, MAZZELLA G, et al.A placebocontrolled trial of obeticholic acid in primary biliary cholangitis[J].N Engl J Med, 2016, 375 (7) :631-643.

[6]SAMUR S, KLEBANOFF M, BANKEN R, et al.Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis[J].Hepatology, 2017, 65 (3) :920-928.

[7]GRIGORIAN AY, MARDINI HE, CORPECHOT C, et al.Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis:a meta-analysis[J].Clin Res Hepatol Gastroenterol, 2015, 39 (3) :296-306.

[8]CHEUNG A, LAPOINTE-SHAW L, KOWGIER M, et al.Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes[J].Aliment Pharmacol Ther, 2016, 43 (2) :283-293.

[9]HOSONUMA K, SATO K, YAMAZAKI Y, et al.A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia[J].Am J Gastroenterol, 2015, 110 (3) :423-431.

[10] RAUTIAINEN H, KARKKAINEN P, KARVONEN AL, et al.Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis:a three-year randomized trial[J].Hepatology, 2005, 41 (4) :747-752.

[11]RABAHI N, CHRETIEN Y, GAOUAR F, et al.Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone[J].Gastroenterol Clin Biol, 2010, 34 (4-5) :283-287.

[12]RAUTIAINEN H, KARKKAINEN P, KARVONEN AL, et al.Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis:a three-year randomized trial[J].Hepatology, 2005, 41 (4) :747-752.

[13]TSUDA M, MORITOKI Y, LIAN ZX, et al.Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid[J].Hepatology, 2012, 55 (2) :512-521.

[14]HIRSCHFIELD GM, GERSHWIN ME, STRAUSS R, et al.Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid:a proof-of-concept study[J].Hepatology, 2016, 64 (1) :189-199.

[15]ZHOU M, LEARNED R, ROSSI S, et al.Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice[J].Hepatology, 2016, 63 (3) :914-929.

[16]HEGADE V, KENDRICK S, DOBBINS R, et al.Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis:a double-blind, randomised, placebo-controlled, crossover, phase 2a study[J].Lancet, 2017, 389 (10074) :1114-1123.

[17]Working Subgroup (English version) for Clinical Practice Guidelines for Primary Biliary Cirrhosis.Guidelines for the management of primary biliary cirrhosis:The Intractable Hepatobiliary Disease Study Group supported by the Ministry of Health, Labour and Welfare of Japan[J].Hepatol Res, 2014, 44 (Suppl 1) :71-90.

[18]LAMMERS WJ, HIRSCHFIELD GM, CORPECHOT C, et al.Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy[J].Gastroenterology, 2015, 149 (7) :1804-1812.e1804.

[19]CARBONE M, SHARP SJ, FLACK S, et al.The UK-PBC risk scores:derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis[J].Hepatology, 2016, 63 (3) :930-950.

[20]TRIVEDI PJ, BRUNS T, CHEUNG A, et al.Optimising risk stratification in primary biliary cirrhosis:AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response[J].J Hepatol, 2014, 60 (6) :1249-1258.

[21]European Association for the Study of the liver.EASL clinical practice guidelines:the diagnosis and management of patients with primary biliary cholangitis[J].J Hepatol, 2017, 67 (1) :145-172.

施引文献

资源附件(0)

访问统计